Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: A Korean Cancer Study Group Trial

Authors

  • Tae Won Kim Section of Oncology, Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
  • Won Ki Kang Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea
  • Heung Moon Chang Section of Oncology, Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
  • Joon Oh Park Division of Hematology-Oncology, Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea
  • Baek Yeol Ryoo Division of Hematology and Oncology, Department of Internal Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Science, Seoul, Korea
  • Jin Seok Ahn Department of Internal Medicine, Hallym University College of Medicine, Hallym Sacred Heart Hospital, Anyang, Korea
  • Dae Young Zang Department of Internal Medicine, Hallym University College of Medicine, Hallym Sacred Heart Hospital, Anyang, Korea
  • Kyung Hee Lee Division of Hematology-Oncology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea
  • Yoon Koo Kang Section of Oncology, Department of Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
  • Sung Rok Kim Department of Internal Medicine, Inje University College of Medicine, Sanggye Paik Hospital, Seoul, Korea
  • Hoon-Kyo Kim Department of Internal Medicine, The Catholic University College of Medicine, St Vincent's Hospital, Suwon, Korea

DOI:

https://doi.org/10.1080/02841860510029590

Abstract

A phase II study was conducted to assess the efficacy and tolerability of capecitabine in combination with irinotecan (CAPIRI) in advanced colorectal cancer. Forty-seven patients with previously untreated metastatic or unresectable colorectal adenocarcinoma received capecitabine 1000 mg/m2 twice daily on days 2–15 and intravenous irinotecan 100 mg/m2 on days 1 and 8, every 21 days. A total of 268 cycles of chemotherapy (median 6: range 1–11) were administered. According to an intent-to-treat analysis, the overall response rate was 49% (95% CI, 35–63%). Median time to progression and overall survival were 7.5 months (95% CI, 4.8–10.2) and 19.5 months (95% CI, 15.7–23.8), respectively. The most common grade 3/4 adverse events were diarrhea (24%) and neutropenia (11%). There were no treatment-related deaths. These results indicate that CAPIRI has comparable activity and tolerability to FOLFIRI as first-line treatment for advanced colorectal cancer.

Downloads

Download data is not yet available.

Downloads

Published

2005-05-01

How to Cite

Won Kim, T. ., Ki Kang, W. ., Moon Chang, H. ., Oh Park, J. ., Yeol Ryoo, B. ., Seok Ahn, J. ., … Kim, H.-K. (2005). Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: A Korean Cancer Study Group Trial. Acta Oncologica, 44(3), 230–235. https://doi.org/10.1080/02841860510029590

Issue

Vol. 44 No. 3 (2005): Acta Oncologica

Section

Articles